SUBSEQUENT EVENTS	9 Months Ended
Mar. 31, 2025
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	NOTE 18 – SUBSEQUENT EVENTS The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined that the following subsequent event needed to be disclosed. On April 3, 2025, the Company received $10,000 in proceeds from a private investor in connection with a private placement of 20,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued. On April 7, 2025, the Company received $50,000 in proceeds from a private investor in connection with a private placement of 100,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued. On April 16, 2025, the Company received $150,000 in proceeds from a private investor in connection with a private placement of 300,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued. On May 7, 2025, the Company received $100,000 in proceeds from a private investor in connection with a private placement of 200,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued. On May 12, 2025, the Company was approved for uplisting from the OTC Pink Market to the OTCQB Venture Market, having met all eligibility requirements. As a result, investors now have access to real time Level 2 quotes for the Company’s securities. enhancing market visibility and transparency. On May 31, 2025, the Company received $100,000 in proceeds from a private investor in connection with a private placement of 200,000 shares of the Company’s common stock. As of the date of this filing, the shares had not yet been issued.

SUBSEQUENT EVENTS

9 Months Ended

Mar. 31, 2025

NOTE 18 – SUBSEQUENT EVENTS

The Company has evaluated all events that occurred after the balance sheet date through the date when the financial statements were issued to determine if they must be reported. The Management of the Company determined that the following subsequent event needed to be disclosed.

On April 3, 2025, the Company received $10,000 in proceeds from a private investor in connection with a private placement of 20,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued.

On April 7, 2025, the Company received $50,000 in proceeds from a private investor in connection with a private placement of 100,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued.

On April 16, 2025, the Company received $150,000 in proceeds from a private investor in connection with a private placement of 300,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued.

On May 7, 2025, the Company received $100,000 in proceeds from a private investor in connection with a private placement of 200,000 shares of the Company’s common stock. As of the date of this filing, the shares have not been issued.

On May 12, 2025, the Company was approved for uplisting from the OTC Pink Market to the OTCQB Venture Market, having met all eligibility requirements. As a result, investors now have access to real time Level 2 quotes for the Company’s securities. enhancing market visibility and transparency.

On May 31, 2025, the Company received $100,000 in proceeds from a private investor in connection with a private placement of 200,000 shares of the Company’s common stock. As of the date of this filing, the shares had not yet been issued.